Dec 20, 2024 · Grifols is a leading global healthcare company. Our trusted and innovative plasma-derived medicines, other biopharmaceuticals and solutions in transfusion medicine enable millions of patients around the world to lead more productive lives.

Grifols is a global healthcare company that since 1909 has enhanced the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, we develop, produce and provide innovative healthcare services and solutions in more than 110 countries.

As Grifols grew into a global plasma leader over the last 50 years, the company became increasingly known for its industrial excellence, with advanced machinery, robotics and equipment for highly sophisticated and efficient manufacturing operations.

At Grifols, we are pioneers in the development of therapies derived from blood and plasma. We contribute to building the future of healthcare to improve people's well-being. Since 1909, we have been defined by passion, innovation, teamwork and a sense of responsibility.

Grifols USA was established in 2003. Based in Los Angeles, we cover the U.S. market where we offer a comprehensive portfolio of Grifols products and services. The company is one of the largest producers of life-saving plasma medicines and other innovative biopharmaceutical solutions in the world.

We trace our roots back to 1909 when Dr. Josep Antoni Grifols i Roig founded the first analysis laboratory in Barcelona: Instituto Central de Análisis Clínicos, Bacteriológicos y Químicos.

A pioneer in the plasma industry, Grifols develops innovative plasma-derived medicines and other biopharmaceutical solutions that treat patients with chronic, rare, and, at times, life-threatening conditions.

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. The company develops, produces, and provides innovative healthcare services and solutions in more than 110 countries.

Grifols treatments center on immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases. Each area features therapies helping patients today as well as boundary-pushing research leading to the next groundbreaking discoveries.

Feb 29, 2024 · As of December 31, 2023, Grifols had a liquidity position of EUR 1,141 million and a cash position of EUR 526 million. Grifols projects sustainable profitable growth for 2024. As Grifols moves into 2024, it is well-positioned to accelerate improvements in financial performance and operational efficiency.